At Inventera, we are dedicated to developing high-performance MRI contrast agents through rigorous clinical trials to address the unmet needs of current diagnostic solutions. As a sponsor, we uphold the highest standards of scientific integrity and ethical responsibility, ensuring that every step of our research prioritizes patient safety and well-being.
Ongoing Trials (Korea)
INV-002 Contrast Agent for MR Arthrography
(Product Name: NEMO-103 Inj.)
INV-002 demonstrated safety with no adverse or drug-related reactions, along with excellent contrast effects in the Phase 1/2a clinical trial in Korea. In the recently completed Phase 2b trial, investigators from multiple university hospitals participated, and a larger cohort of participants underwent both quantitative and qualitative efficacy evaluations, as well as comprehensive safety assessments. We are working to initiate the Phase 3 trial in 2025.
INV-001 Contrast Agnet for MR Lymphangiography
(Product Name: INV-001 Inj.)
INV-001 has demonstrated safety in non-clinical trials across a range of species, from small to large animals, even at doses hundreds of times higher than those planned for clinical use. It has also shown superior contrast effects without venous contamination, a limitation of existing contrast agents. To validate these results in humans, we are currently progressing through Phase 1/2a clinical trials.